Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01244490 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 338
- Enrollment target
NCT01244490 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 338 participants.
The verdict
NCT01244490, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 338 participants
- Enrollment target
Study Summary
For children and adolescents, how does SPD503 compare to placebo for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
Interventions
- DRUG Placebo Comparator
- DRUG Atomoxetine Hydrochloride
- DRUG Extended-release Guanfacine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2011-01-17 |
| Est. Completion | 2013-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01244490
The ClinicalTrials.gov registry entry for NCT01244490 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Comparator is the first listed.
NCT01244490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01244490 about?
NCT01244490 is a clinical study titled "Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)". For children and adolescents, how does SPD503 compare to placebo for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
What is the current status of trial NCT01244490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 338 participants. The study started on 2011-01-17. Estimated completion is 2013-05-01.
What interventions are being tested in trial NCT01244490?
The interventions under investigation include: Placebo Comparator (DRUG), Atomoxetine Hydrochloride (DRUG), Extended-release Guanfacine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01244490?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.